

FFR CT : STATE OF THE ART IN THE EVALUATION OF CORONARY ARTERY DISEASE

MD. Andrea J. Robaina Barrios

President of Interventional Cardiology Venezuelan Society (SOVECI)


Interventional Cardiologist.

Definition: Non-invasive physiological simulation technique that models coronary blood flow dynamics from CT angiography.

Calculates the ratio of maximum blood flow distal to a stenosis to the theoretical maximum flow without disease.



It uses Computational Fluid Dynamics (CFD) or Machine Learning algorithms.

Interpretation Values →




INTRODUCTION TO CT-FFR

Clinical practice of FFR_{CT}




INTRODUCTION TO CT-FFR





Evaluation of Intermediate Stenosis (50-90%)

Helps determine the actual hemodynamic significance of the injury.
Guide to decisions on revascularization vs. medical therapy.
CAD-RADS 2.0 recommends CT-FFR for CAD-RADS 3 and 4a stenoses.




Pre-procedural Planning (PCI/CABG):

Sheath/catheter selection, optimal stent lengths, fluoroscopic angles.
Precise phenotyping of CAD, tailoring revascularization strategies.





Pre-procedural Planning (PCI/CABG):

Virtual stenting planner



ACS:



In high-risk NSTEMI-ACS: Diagnostic precision superior and greater ability to rule out hemodynamically significant stenoses to CT angiography (sensitivity 94%, specificity 63% at the patient level).




Study location/timeline 4 European centres 2019-2022 (stopped at 2/3 of the sample size)	Patient population 164 high-risk ACS patients Median hs-TnT level: 5.3 (IQR 1.8-18.6) × URL	Study objectives Capacity of FFR-CT and CCTA to rule out significant lesions (patient and vessel level) assessed by a core laboratory
---	--	---

Stable Chest Pain:

Effective tool that minimized the number of invasive procedures and increased the revascularization.
FFRCT has been associated with a better over all diagnostic precision and a higher sensitivity than perfusion imaging with SPECT and magnetic resonance.



CLINICAL APPLICATIONS AND INDICATIONS




Comparative Performance vs. CT FFR and CT Angiography:


Diagnostic Metric	CT-FFR (Per Patient)	Coronary CT Angiography (Per Patient)	CT-FFR (Per Vessel)	Coronary CT Angiography (Vessel)
Sensitivity	89% (IC 95%: 85-92%)	93% (Meta-analysis)	85% (IC 95%: 82-88%)	88% (Meta-analysis)
Specificity	71% (IC 95%: 61-80%)	32% (Meta-analysis)	82% (IC 95%: 75-87%)	46% (Meta-analysis)
Precision	~84% (DISCOVER-FLOW)	~59% (DISCOVER-FLOW)	N/A	N/A
	81% (NXT)	53% (NXT)	N/A	N/A
PPV (Positive Predictive Value)	83% (from SCASEST)	79% (from SCASEST)	67% (from SCASEST)	56% (from SCASEST)
NPV (Negative Predictive Value)	85% (from SCASEST)	80% (from SCASEST)	92% (from SCASEST)	92% (from SCASEST)

FFRCT : its ability to significantly increase the specificity of coronary CT angiography in the evaluation of CAD.
 Superior diagnostic performance of FFRCT compared with anatomic interpretation by coronary CT angiography alone.

CLINICAL EVIDENCE



CLINICAL EVIDENCE



COMPARISON OF DIFFERENT CT FFR SUPPLIERS AND PRODUCTS

Company/Organization	Production	Characteristic	Individuals		Vessels		Approval
			Sensitivity (%)	Specificity (%)	Sensitivity (%)	Specificity (%)	
HeartFlow	FFRCT	Primary 3D-CFD	86	79	84	86	FDA (2014)
Siemens	cFFR	On-site	87	86	—	—	Cooperate with HeartFlow (2017)
Toshiba	CT-FFR	Reduced 3D-CFD	77.8	76.8	—	—	—
RuiXin	RuiXin-FFR	Multi-layer deep learning	87	88	—	—	MDR (2023), NMPA (2021)
United Imaging	uCT-FFR	AI computing	89	91	—	—	NMPA (2024)
Shukun Technology	Shukun-FFR	AI computing	96.2	93.1	83.6	96.3	NMPA (2023)
YueYing	MaiYing®esFFR	3D-CFD	—	—	—	—	NMPA (2022)
KeYa	CT-FFR	3D-CFD	93.6	88.2	93.9	90.4	FDA (2022), NMPA (2020), CE (2018),
Affiliated Jinling Hospital, Medical School of Nanjing University	CT-FFR	Fully automatic, on-site	84	81	—	—	Under testing (2024)

IMPACT ON CLINICAL MANAGEMENT AND CARE PATHWAYS

Reduction of Unnecessary ACI:

Patients with normal CT-FFR can be safely deferred from ACI.

In high-risk NSTEMI-ACS, it can avoid more than 60% of unnecessary invasive evaluations. Increase in optimal medical therapy.

Optimization of Treatment Strategies:

More precise decisions regarding revascularization vs. medical therapy, especially in intermediate stenoses.

In situ CT-FFR improves patient selection for ACI.

Profitability Considerations:

Historically, slow and expensive post-processing.

Savings potential by avoiding costly ACI.

Higher costs for CT-FFR (£2,102-£3,913 per patient) vs. conventional stress imaging (£1,411-£2,148).

Profitability varies depending on the system and the comparative diagnostic pathway.

	Recommendations for the Use of CT-FFR	Contraindications/Situations Not Recommended
<p>Society for Cardiovascular Computed Tomography (SCCT) / CMS</p> <p>CAD-RADS 2.0 / 2021 (CMS Coverage Guide)</p>	<p>Defines the hemodynamic relevance of stenoses.</p> <p>Reasonable and necessary in intermediate-risk patients with acute or stable chest pain and 40%-90% stenosis on coronary CT angiography.</p>	<p>Previous prosthetic valves or bypass grafts,</p> <p>Bare-metal stents,</p> <p>Post-heart transplant, recent MI (<30 days),</p> <p>Pacemaker/defibrillator,</p> <p>Stenosis >90% or <40% does not require FFRct.</p>

LIMITATIONS, CHALLENGES AND PRACTICAL CONSIDERATIONS

ADVANTAGES

Allows anatomical and functional evaluation in a single test.

No need for additional testing for patients.

No need for additional contrast.

No need for additional radiation.

Assesment of lesion specific ischemia.

May prevent unnecessary invasive coronary angiograms.

Determine physiological pattern of disease and focal pressure gradients.

Using virtual stenting tools can guide revascularization strategies.

DISADVANTAGES

Not useful for distal lesions. (Best for prox and mid vessels).

Not useful for vessels with stents.

Lees reliable with extensive calcifications.

Highly dependent on image quality.

Additional cost and reimbursement can be challenging.

Offsite analysis challenges usage in urgent settings.

FUTURE DIRECTIONS

Emerging Technologies and Algorithms.

AI/Deep Learning: Will improve accuracy, reduce times, overcome limitations (artifacts, calcification).

On-site solutions: Streamline clinical workflows.

Expansion of Clinical Indications.

Randomized controlled trials in high-risk populations to assess impact on hard endpoints and cost-effectiveness.

Objective: Minimize unnecessary invasive procedures, optimize patient outcomes.

AI-Clinical Convergence: AI-powered CT-FFR as an indispensable tool in precision cardiology.

EXECUTIVE SUMMARY / CONCLUSIONS

CT-FFR: Noninvasive evaluation of CAD, deriving physiological information from coronary CT angiography.

Strong evidence from indexed journals and trials: Superior accuracy and prognostic value.

Overcomes the limitation of CT Angiography: Anatomy does not always correlate with functional ischemia.

Invasive Gold Standard (FFR) vs. Noninvasive CT-FFR: Closing the Gap.

Benefits: Reduces unnecessary invasive procedures, optimizes revascularization, improves outcomes.

